Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets

Klingenberg, Marcel; Matsuda, Akiko; Diederichs, Sven; Patel, Tushar

doi:10.1016/j.jhep.2017.04.009

Cited by 313 publications

(280 citation statements)

References 210 publications

Supporting

Mentioning

269

Contrasting

Order By: Relevance

“…The results showed that AUC for plasma DANCR was 0.868 which was higher than that for AFP (AUC = 0.744) when differentiating patients with HCC from non-HCC patients [112] . Besides these circulating lncRNAs, JPX, UCA1 and WRAP53 were found increased in HCC patients [106,113,114] alone or in combination with other lncRNAs, miRNAs or serum biomarkers [115] . Many reports have indicated that the deregulation of lncRNAs plays important roles in occurrence and progression of HCC however further studies are needed in order to use these as biomarkers.…”

Section: Circulating Non-coding Rnamentioning

confidence: 97%

Performance of different biomarkers for the management of hepatocellular carcinoma

Rojas¹,

Sánchez‐Torrijos²,

Gil‐Gómez³

et al. 2018

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second cause of cancer related death due to latent liver disease, late diagnosis and non-available therapeutic treatment. Liver biopsy is still the gold standard in order to know the molecular biology of the tumor, its behaviour and invasive characteristics. Conventional diagnosis methods for HCC detection include imaging and serological tests with low sensitivity and specificity. In this review, we focus on the potential utility of certain serum biomarkers and a new approach, "liquid biopsy", in the management of HCC patients.

show abstract

Section: Circulating Non-coding Rnamentioning

confidence: 97%

Performance of different biomarkers for the management of hepatocellular carcinoma

Rojas¹,

Sánchez‐Torrijos²,

Gil‐Gómez³

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Aberrant expression of lncRNAs has been observed in many types of cancers [11-13]. Previous profile studies of lncRNA expression have documented the dysregulation of a series of lncRNAs in HCC including LncRNA DQ786243 (LncDQ) [14].…”

Section: Introductionmentioning

confidence: 99%

Upregulation of LncDQ is Associated with Poor Prognosis and Promotes Tumor Progression via Epigenetic Regulation of the EMT Pathway in HCC

Zeng

Lin

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Long noncoding RNAs (lncRNAs) are key regulators of cancer initiation and progression. In this study, we investigated the clinical value and functional role of LncRNA DQ786243 (LncDQ) in the pathogenesis of hepatocellular carcinoma (HCC). Methods: To investigate the expression level of LncDQ in HCC, we performed quantitative real-time PCR using total RNA extracted from HCC tumor tissues and their matched non-neoplastic counterparts, as well as from the serum of HCC patients and healthy volunteers. The correlation of LncDQ expression with clinicopathologic features and prognosis was analyzed. The functional role of LncDQ in cell proliferation, migration, and invasion were evaluated by MTT cell viability, wound healing, and transwell assays in vitro and in vivo. RNA immunoprecipitation and chromatin immunoprecipitation assays were performed to analyze the potential mechanism of LncDQ in HCC cells. Results: LncDQ was upregulated in both HCC tissue samples and serum and was correlated with low survival rate and adverse clinical pathological characteristics. Multivariate analysis demonstrated that LncDQ expression was an independent prognostic factor for HCC. The area under the receiver operating characteristic curve was 0.804 with a sensitivity of 0.72 and a specificity of 0.8. Knockdown of LncDQ induced inhibition of cell proliferation, migration, and invasion in vitro and in vivo. Mechanistically, LncDQ regulated the epithelial–mesenchymal transition pathway by interacting with EZH2, to epigenetically repress the expression of E-cadherin in HCC cells. Conclusions: Taken together, the results of our study indicate that LncDQ plays a critical role in HCC progression, and may serve as a potential diagnostic and prognostic biomarker for HCC.

show abstract

“…20 This study showed that RP11 is associated with elevated EMT as well as poor prognosis in 75 patients with liver cancer. 20 This study showed that RP11 is associated with elevated EMT as well as poor prognosis in 75 patients with liver cancer.…”

Section: Discussionmentioning

confidence: 74%

Dependence of artesunate on long noncoding RNA‐RP11 to inhibit epithelial‐mesenchymal transition of hepatocellular carcinoma

Dong

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

As a first line medicine for malaria treatment, artesunate (ART) also shows antitumor potential. However, little is known about the effect of ART on the cancer cell epithelial‐mesenchymal transition (EMT). In this study, we found that ART inhibited cell growth in SK‐HEP1 and SM7721 hepatocellular carcinoma cell lines. A microarray was used to identify differentially expressed protein‐coding RNAs (pcRNA) and long noncoding RNAs (lncRNA) between SK‐HEP1 cells with and without ART treatment. A differentially expressed lncRNA—RP11, the most related to the EMT of liver cancer cells—RP11 was identified by abioinformatics method Overexpressing and silencing assays were used to verify the role of RP11 in cancer cell EMT. The levels of RP11‐ and EMT‐related genes in liver cancer samples from 75 patients were detected by using qualitative polymerase chain reaction or immunohistochemistry. We identified 1334 pcRNAs and 1670 lncRNA with differential expression induced by ART. ART inhibits EMT, proliferation, migration, invasion, and adhesion of liver cancer cells. RP11 depresses the inhibitory effect of ART on cancer cell EMT. The level of RP11 is associated with cancer cell EMT and metastasis and survival rate of the patient. These data suggest that RP11‐linking ART and cancer cell EMT are important for ART‐inhibited metastasis of liver cancer.

show abstract

Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets

Cited by 313 publications

References 210 publications

Performance of different biomarkers for the management of hepatocellular carcinoma

Performance of different biomarkers for the management of hepatocellular carcinoma

Upregulation of LncDQ is Associated with Poor Prognosis and Promotes Tumor Progression via Epigenetic Regulation of the EMT Pathway in HCC

Dependence of artesunate on long noncoding RNA‐RP11 to inhibit epithelial‐mesenchymal transition of hepatocellular carcinoma

Contact Info

Product

Resources

About